Psychiatric Annals
June 1, 2024
Syed Iqbal, Ronak Patel, Zeshan Barlas et al.
Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist that has antidepressant and antisuicidal effects, as shown by multiple studies done over the past two decades, that can be used effectively in the management of treatment-resistant depression (TRD). The United States Food and Drug Administration has approved intranasal (S)-ketamine in combination with an oral antidepressant for TRD....
Psychiatric Annals
December 1, 2023
Fernando Espí Forcén
3 citations
Hispanic and Latinx people practice spirituality in a wide array of forms. Whereas Catholicism has been the dominant religion for centuries, a re-birth of Native American and African spirituality has taken place over the last few decades. In parallel, the influence of the United States in the Latin world is reflected in the rapidly growing popularity of Evangelical Christianity. In order to...
Psychiatric Annals
December 1, 2022
Justin Morales, Erik Quan, Arslaan Arshed et al.
27 citations
As psychedelic-assisted therapy research and clinical trials continue to grow, there is a positive outlook on the future, but also concerns about who will benefit. Most research shows that there is an obvious deficit of racial and ethnically minoritized populations, defined within the article, enrolling in studies. The objectives of this paper are (1) to provide a history of psychedelics and...
Psychiatric Annals
September 1, 2022
Brian S. Barnett, Jeremy Weleff
6 citations
Growing evidence from observational studies and clinical trials suggests that psychedelics such as lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, and psilocybin may hold treatment potential for alcohol, opioid, tobacco, and other substance use disorders (SUDs). The mechanisms by which psychedelics might exert therapeutic efficacy in these conditions have not been fully...
Psychiatric Annals
September 1, 2022
Mitch Earleywine, Zachary Herrmann
5 citations
Initial promise and dire need have inspired the multiple research programs of the second psychedelic renaissance. Serotonergic psychedelics (psilocybin, lysergic acid diethylamide, and ayahuasca) have decreased end-of-life anxiety in cancer patients, treatment-resistant depression, alcohol dependence, social anxiety in autistic adults, and nicotine dependence when applied with supportive...
Psychiatric Annals
September 1, 2022
Michael Ljuslin, Kabir Nigam, Roxanne Sholevar et al.
4 citations
In addition to physical symptoms and treatment burden, people affected by serious illness experience psychological, social, and spiritual distress. Medical professionals who care for them, including psychiatrists and other mental health clinicians, attend to these multiple dimensions of suffering with the hope and promise of improving patients' quality of life. Yet anxiety, depression,...
Psychiatric Annals
September 1, 2022
Fernando Espí Forcén, Maren Nyer
To date, ketamine is the only prescribable psychedelic medicine in the United States. Ketamine is also one of the most promising drugs for the treatment of depression. In the current paradigm of care, most ketamine clinics in the United States treat patients with mood disorders with ketamine and its derivatives alone without psychotherapy. The purpose of this article is to review the most...
Psychiatric Annals
February 1, 2020
Lynnette A. Averill, Christopher L. Averill, Chadi G. Abdallah
6 citations
The serendipitous discovery of ketamine's robust antidepressant effects has served as a major catalyst to usher in new era of drug development and a paradigm shift in our understanding of the neurobiology of chronic stress pathology (CSP). This review provides a selective synthesis of (1) the historical foundations of N-methyl-D-aspartate receptor modulators and the path to discovering...
Psychiatric Annals
February 1, 2020
Hatice Guncu Kurt, Murat Altinay, Amit Anand
Patients who have not responded to two antidepressant trials in their current depressive episode are usually considered to have treatment-resistant depression (TRD). A detailed search on PubMed was conducted for reported response and remission rates for non-ketamine and ketamine treatments for TRD. From a variety of pharmacological and brain stimulation open-label studies, the treatments were...
Psychiatric Annals
March 1, 1994
David M. Mcdowell, Herbert D. Kleber
75 citations
MDMA has been effectively illegal since it was classified as a Schedule I drug in July 1985.
Psychiatric Annals
March 1, 1994
George K. Aghajanian
27 citations
By the early 1960s the 5-HT hypothesis of the action of LSD had become firmly established in the field.
Psychiatric Annals
March 1, 1994
Mark S. Gold
11 citations
Use of LSD, and hallucinogens in general, appears to be increasing, according to surveys of high school students.
Psychiatric Annals
March 1, 1994
David E Smith, Richard B. Seymour
3 citations
Today, there is growing concern over long-term posthallucinogen perceptual disorder.
Psychiatric Annals
March 1, 1994
Robert L. Dupont, Karl Verebey
1 citation
LSD and Ecstasy and other hallucinogenic drugs (especially psilocybin mescaline) are in an anomalous position as frequently abused, widely available illicit drugs that are rarely identified in drug tests.
Psychiatric Annals
March 1, 1993
Uriel Heresco-Levy, Daniel C Javitt, Stephen R Zukin
The hyperdopaminergic theory of schizophrenia cannot account for many dimensions of the illness.